Latest Content

Catch up on the top stories in optometry during the week of September 7-September 11.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Mogenry (sonpiretigene isteparvovec, MC-010) is a gene therapy for retinitis pigmentosa with severe vision loss.

Heru's PretestPro runs 4 pretesting exams in about 90 seconds on the Heru Prime wearable platform and reaches all current and future customers via free software update.

In the first episode of the second season of The Independent Advantage, Diana Canto-Sims, OD, chats with practice owner Maria Sampalis, OD, on why artificial intelligence has boomed in practice ownership spaces.

The latest in drug and technology developments and updates from August 2026.

Merabet, OD, PhD, MPH, discusses what his research on motion processing reveals about the neural roots of CVI and where diagnostic tools like neuroimaging and eye tracking are headed.

Host Hamza Shah, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension, inspired by Mitchell et al's paper, "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial."

Periocular skin treatment is emerging as a complementary treatment for dry eye disease.

SightGlass Vision reports the milestone just 1 year after reaching 1 million users.

The industry-sponsored survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Acoltremon ophthalmic solution 0.003% usage was associated with improved performance in visual acuity tasks.

The OTC lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.